Cardiovascular Risk Assessment and Lipid-Lowering Therapy Recommendations in Primary Prevention DOI Open Access

Aikaterini Komnianou,

Konstantinos G. Kyriakoulis, Ariadni Menti

и другие.

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(7), С. 2220 - 2220

Опубликована: Март 25, 2025

Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, underscoring importance effective primary prevention strategies. Current total cardiovascular (CVD) risk assessment tools, such as Systematic Coronary Risk Evaluation 2 (SCORE2) in Europe Pooled cohort equations (PCEs) Predicting CVD EVENTs (PREVENT) USA, aim to identify individuals at high guide clinical decision-making setting. Statin therapy reduces events is recommended first step for with estimated above specific thresholds. Moreover, presence modifiers, well detection asymptomatic atherosclerosis, reclassifies low-moderate into higher categories, contributing tailored therapeutic decisions prevention. However, differences performance available thresholds intervention, treatment targets by scientific societies introduce considerable inconsistency statin practices. In addition, physicians' inertia poor patients' adherence contribute inadequate dyslipidemia control rates. This narrative review examines evidence on current most used tools respective lipid-lowering recommendations, highlights role targeted screening atherosclerosis terms individualized

Язык: Английский

Cardiovascular Risk Assessment and Lipid-Lowering Therapy Recommendations in Primary Prevention DOI Open Access

Aikaterini Komnianou,

Konstantinos G. Kyriakoulis, Ariadni Menti

и другие.

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(7), С. 2220 - 2220

Опубликована: Март 25, 2025

Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, underscoring importance effective primary prevention strategies. Current total cardiovascular (CVD) risk assessment tools, such as Systematic Coronary Risk Evaluation 2 (SCORE2) in Europe Pooled cohort equations (PCEs) Predicting CVD EVENTs (PREVENT) USA, aim to identify individuals at high guide clinical decision-making setting. Statin therapy reduces events is recommended first step for with estimated above specific thresholds. Moreover, presence modifiers, well detection asymptomatic atherosclerosis, reclassifies low-moderate into higher categories, contributing tailored therapeutic decisions prevention. However, differences performance available thresholds intervention, treatment targets by scientific societies introduce considerable inconsistency statin practices. In addition, physicians' inertia poor patients' adherence contribute inadequate dyslipidemia control rates. This narrative review examines evidence on current most used tools respective lipid-lowering recommendations, highlights role targeted screening atherosclerosis terms individualized

Язык: Английский

Процитировано

0